Skip to main content
. Author manuscript; available in PMC: 2017 Oct 12.
Published in final edited form as: JAMA. 2011 May 11;305(18):1873–1881. doi: 10.1001/jama.2011.593

Figure 4.

Figure 4

Subset analysis of genomic predictions in the validation cohort: ER+/HER2− (A), ER−/HER2−(B), taxane chemotherapy administered as 12 cycles of weekly paclitaxel (C) or 4 cycles of 3-weekly docetaxel (D). P-values are from the log-rank test.